Current Report · Items 3.01, 7.01, 9.01 · 8-K
Palatin Technologies, Inc.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Regulation FD Disclosure
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 18, 2026, Palatin Technologies, Inc. (the “Company”), acting pursuant to authorization from its Board of Directors, provided notice to the NYSE American LLC (the “NYSE”) that it intends to voluntarily withdraw the listing of its common stock, par value $0.01 per share (the “common…
Filed May 18, 2026Accepted May 18, 2026, 5:07 PM EDTCIK 911216Accession 0001493152-26-024219
Company context
We are a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Current securities
Historical securities (5)
Registered securities in this filing
PALATIN TECHNOLOGIES, INC. · 8-K · Filed 2026-05-18
As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.
Common Stock, par value $0.01 per share
- Symbol
- PTN
- Exchange
- NYSE
- Classification
- COMMON
Filing context
Context: AsOf2026-05-18
Dimensions: Not supplied
Accession 000149315226024219 · 1 registered-security cover member
Read the exact SEC filing ↗Disclosure sections
Items 3.01, 7.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 3.01Item 3.01 - Notice of Delisting
Item 3.01. Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
May 18, 2026, Palatin Technologies, Inc. (the “Company”), acting pursuant to authorization from its Board of Directors, provided
notice to the NYSE American LLC (the “NYSE”) that it intends to voluntarily withdraw the listing of its common stock, par
value $0.01 per share (the “common stock”), from the NYSE and transfer the listing of its common stock to the Nasdaq Capital
Market (the “Nasdaq”). The Nasdaq has approved such listing. The Company expects the listing and trading of its common stock
on the NYSE to cease at the close of trading on May 28, 2026. The Company expects the common stock to begin trading on the Nasdaq on
May 29, 2026. The common stock will continue to trade under the symbol “PTN”.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation
FD Disclosure.
The
Company issued a press release on May 18, 2026 announcing the transfer of the listing of its common stock from the NYSE to Nasdaq. The
press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The
information in Item 7.01, including Exhibit 99.1, of this Current Report on Form 8-K is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities
Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by
specific reference in such a filing.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htmEX-99.1
2
ex99-1.htm
EX-99.1
Exhibit
99.1
Palatin
to Begin Trading on Nasdaq Stock Exchange
PRINCETON,
NJ - May 18, 2026 /PRNewswire/ - Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on
the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock
has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from
the NYSE American.
The
Company expects to begin trading as a Nasdaq-listed company on May 29, 2026, and will continue to trade under the symbol “PTN.”
Palatin’s common stock will continue to trade on the NYSE American until the market close on May 28, 2026.
“We
are pleased to announce our listing on the Nasdaq Capital Market and to join a community of leading biotechnology companies,” said
Carl Spana, Ph. D., President and Chief Executive Officer of Palatin Technologies. “We believe the move to Nasdaq will improve the
visibility of our common stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors.”
Palatin
is advancing selective MC4…
Open exhibit ↗